Related Experiment Video

Updated: Jul 1, 2026

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

The IL-33/ST2 pathway to modulate the inflammatory microenvironment: A new therapeutic target in chronic obstructive

Xiaoyan Xie1, Lei Yang1, Jie Chen2

  • 1Department of Pharmacy, Jianyang People's Hospital, Jianyang, 641400, China.

Biochemistry and Biophysics Reports
|June 30, 2026
PubMed

Insights

The IL-33/ST2 pathway is key in chronic obstructive pulmonary disease (COPD) progression. Targeting this pathway shows promise for treating COPD by reducing inflammation and exacerbations.

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Molecular Biology

Background:

  • The IL-33/ST2 pathway plays a critical role in chronic obstructive pulmonary disease (COPD) pathogenesis.
  • Elevated IL-33 and ST2 levels in COPD patients correlate with disease severity and poor outcomes.

Purpose of the Study:

  • To review the molecular mechanisms of the IL-33/ST2 pathway in COPD.
  • To summarize its role in COPD development, treatment, and immune-inflammatory regulation.
  • To explore therapeutic strategies targeting IL-33/ST2 for COPD drug discovery.

Main Methods:

  • Literature review focusing on IL-33/ST2 pathway in COPD.
  • Analysis of molecular characteristics and biological mechanisms.
  • Summary of preclinical therapeutic study findings.

Main Results:

  • IL-33/ST2 pathway dysregulation contributes to oxidative stress, inflammation, and lung injury in COPD.
  • Therapeutic targeting (e.g., antibodies, inhibitors) shows potential in preclinical models.
  • Reduced inflammation, improved lung function, and fewer exacerbations observed.

Conclusions:

  • The IL-33/ST2 pathway is a significant therapeutic target for COPD.
  • Further research is needed to fully understand regulatory mechanisms and crosstalk with inflammation.
  • Targeting IL-33/ST2 offers prospects for novel COPD treatments and drug discovery.
Keywords:
COPDIL-33/ST2Immune microenvironmentInflammatory responseTargeted therapy

More Related Videos

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.